AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026)

AbCellera Biologics' Other Operating Expenses history runs 7 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• Quarterly Other Operating Expenses rose 28.27% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.0 million (up 40.17% YoY) and the FY2025 annual result came in at $22.2 million, down 75.6% from the prior year.
• Other Operating Expenses was $6.8 million for Q1 2026 at AbCellera Biologics, up from -$2.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $77.9 million in Q3 2024 and bottomed at -$108.6 million in Q4 2024.
• A 5-year average of $15.5 million and a median of $9.3 million in 2023 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 746.33% in 2024, while the deepest fall reached 2964.84% in 2024.
• AbCellera Biologics' Other Operating Expenses stood at $18.1 million in 2022, then sank by 119.62% to -$3.5 million in 2023, then sank by 2964.84% to -$108.6 million in 2024, then soared by 97.57% to -$2.6 million in 2025, then soared by 359.61% to $6.8 million in 2026.
• Business Quant data shows ABCL's Other Operating Expenses at $6.8 million in Q1 2026, -$2.6 million in Q4 2025, and $60.3 million in Q3 2025.